Core Laboratories annual stock-based compensation
2021
2022
2023
2024
2025
Core Laboratories Stock-Based Compensation Growth & History (CLB)
Core Laboratories's stock-based compensation was $7.1M for fiscal 2025.
View full Core Laboratories company overviewCore Laboratories annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $7.1M | $3.4M | +90.07% |
| 2024 | 2024-12-31 | $3.8M | −$10.2M | −73.12% |
| 2023 | 2023-12-31 | $14.0M | $6.2M | +80.13% |
| 2022 | 2022-12-31 | $7.8M | −$11.3M | −59.38% |
| 2021 | 2021-12-31 | $19.1M | — | — |
Core Laboratories quarterly stock-based compensation
Q3.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $902,000 | $364,000 | +67.66% |
| Q1 2026 | 2026-03-31 | $5.0M | $873,000 | +20.99% |
| Q4 2025 | 2025-12-31 | $1.1M | — | — |
| Q3 2025 | 2025-09-30 | $1.3M | — | — |
| Q2 2025 | 2025-06-30 | $538,000 | — | — |
| Q1 2025 | 2025-03-31 | $4.2M | −$661,000 | −13.71% |
| Q1 2024 | 2024-03-31 | $4.8M | −$4.2M | −46.35% |
| Q4 2023 | 2023-12-31 | $1.6M | — | — |
| Q3 2023 | 2023-09-30 | $2.1M | −$165,000 | −7.39% |
| Q2 2023 | 2023-06-30 | $1.4M | — | — |
| Q1 2023 | 2023-03-31 | $9.0M | — | — |
| Q3 2022 | 2022-09-30 | $2.2M | — | — |
Core Laboratories stock-based compensation trends
Between the periods ended 2021-12-31 and 2025-12-31, Core Laboratories's stock-based compensation decreased from $19.1M to $7.1M, a change of −$12.0M. The latest reported quarter, Q2 2026, shows $902,000.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Core Laboratories source filings ↗